Next Generation ADCC Enhancement With CoreX Platform Technology
Next Generation ADCC Enhancement With CoreX Platform Technology
Score Pharma is developing new, more potent antibody therapeutics by transforming existing clinically proven antibody therapeutics for an improved patient response.
Our team is prioritizing cancer therapies such as non-Hodgkin lymphoma (NHL),
Chronic Lymphocytic Leukemia (CLL), and HER2-positive breast cancer.
By enhancing existing technologies with a patent-pending improvement process, we expect better therapies with a higher probability of clinical and regulatory success.
With roots in Huntsville, Alabama, Score Pharma relies on strategic partnerships, dedicated Alabama resources, and a distributed virtual team to bring innovation to existing therapies. Contact us to learn more about how you may become a part of this exciting initiative to improve patient health.
Copyright © 2024 Score Pharma, Inc. - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.